HLA-DQB1 is the major histocompatibility complex (class II) antigens that have been identified as useful biomarkers of candidacy for effective allergy immunotherapy in patients with AR (Yanming et al., 2019). The gene discussed is HLA-DQB1; the disease is allergic disease.